Enliven Therapeutics, Inc. SEC filings ELVN
Enliven Therapeutics, Inc. has 798 filings in SEC EDGAR's recent list, going back to Apr 21, 2016. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 12, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 11, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 3, 2026 | Mar 3, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 7, 2026 | Jan 6, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 11, 2025 | Dec 9, 2025 |
| 8-K/A |
Amended current report
Results of operations
|
Nov 13, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2025 | Aug 13, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2025 | Jun 24, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 16, 2025 | Jun 13, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 13, 2025 | Jun 13, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 13, 2025 | Mar 13, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 18, 2024 | Jun 18, 2024 |
| 8-K/A |
Amended current report
Officer or director change
|
May 29, 2024 | Apr 8, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 8-K |
Current report
Other events
|
Apr 11, 2024 | Apr 11, 2024 |
| 8-K |
Current report
Officer or director change
|
Apr 9, 2024 | Apr 8, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Mar 19, 2024 | Mar 19, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 14, 2024 | Mar 14, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Jun 26, 2023 | Jun 23, 2023 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jun 23, 2023 | Jun 23, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 8-K/A |
Amended current report
Regulation FD disclosure, Other events
|
Mar 21, 2023 | Feb 23, 2023 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Other events
|
Mar 1, 2023 | Feb 23, 2023 |
| 8-K |
Current report
Change to shareholder rights, Officer or director change, Bylaw or fiscal year change, Shareholder vote results, Other events
|
Feb 22, 2023 | Feb 22, 2023 |
| 8-K |
Current report
Other events
|
Feb 13, 2023 | Feb 13, 2023 |
| 8-K |
Current report
Other events
|
Dec 5, 2022 | Nov 28, 2022 |
| 8-K/A | Amended current report | Nov 16, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Acquisition or sale of assets, Shareholder vote results
|
Nov 10, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Other events
|
Oct 14, 2022 | Oct 13, 2022 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 13, 2022 | Oct 13, 2022 |
| 8-K |
Current report
Material agreement, Officer or director change, Other events
|
Sep 7, 2022 | Sep 6, 2022 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Jul 29, 2022 | Jul 25, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2022 | Jun 2, 2022 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
Apr 14, 2022 | Apr 5, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 15, 2022 | Mar 15, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2021 | Nov 9, 2021 |
| 8-K |
Current report
Officer or director change
|
Oct 25, 2021 | Oct 21, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2021 | Aug 6, 2021 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 14, 2021 | Jul 13, 2021 |
| 8-K |
Current report
Other events
|
Jul 13, 2021 | Jul 13, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jun 30, 2021 | Jun 29, 2021 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Jun 11, 2021 | Jun 8, 2021 |
| 8-K |
Current report
Results of operations
|
May 11, 2021 | May 11, 2021 |
| 8-K |
Current report
Material agreement
|
Apr 1, 2021 | Apr 1, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2021 | Mar 5, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2020 | Nov 5, 2020 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2020 | Aug 14, 2020 |
| 8-K |
Current report
Results of operations
|
May 7, 2020 | May 7, 2020 |
| 8-K |
Current report
Officer or director change
|
Apr 23, 2020 | Apr 22, 2020 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 16, 2020 | Mar 16, 2020 |
Showing 61 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELVN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Burlingame, CA
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1672619
- Former names
- IMARA Inc. (until Feb 23, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.